xMAP
The firm said that its Verigene II multiplex system is on track to launch in mid-2020 among a number of new products scheduled for release this year.
Luminex Q4 Revenues Rise 12 Percent
The firm submitted its Verigene II Gastrointestinal Flex Assay to the FDA in Q4 and expects to submit Verigene II Respiratory Flex Assay to the agency in Q1 2020.
Food Allergy Dx Firm AllerGenis, Luminex Ink Test Development Deal
AllerGenis has the non-exclusive right to use the xMAP technology to develop, market, and sell a precision food allergy diagnostic assay.
The company claims its test can detect the Lyme-linked chemokine CXCL13 in human cerebrospinal fluid within 20 minutes.